PubHawk
Mol Oncol June 2023 PMID 36550750

JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.

Marco V Haselager, Rachel Thijssen, Danique Bax, Demi Both, Francien De Boer, Simon Mackay, Julie Dubois, Clemens Mellink, Arnon P Kater, Eric Eldering

Full text PDF Download social card

Mentions

5
Peak: 2 in Mar 2023
across 3 sources since Mar 2023

Extended reach

2,831
potential audience

Total likes

7

Video views

41

Mentions per month

Mar 2023 – Sep 2023

Where it's discussed

  • X / Twitter2 posts
  • Blogs2 articles
  • YouTube1 videos

AI synopsis

What people are saying

Several discussions praise the study for elucidating how cytokines like IL21 and IL4 modulate BclXL via JAK-STAT pathways, with phrases such as 'game-changing insights' and 'potential for overcoming resistance' indicating excitement and recognition of their impact. The tone varies from analytical to optimistic, reflecting both appreciation and curiosity about future applications.

AgreementStrong agreement

Most discussions show strong agreement with the article's findings, emphasizing the importance of JAK-STAT and NFB pathways in CLL treatment resistance.

InterestHigh interest

Participants express high interest, highlighting the potential for new therapies and the mechanistic insights provided.

EngagementModerate engagement

Comments reflect thoughtful engagement, with some referring to specific pathways and possible therapeutic targets, though some are more general.

ImpactModerate impact

The dialogues suggest the research could influence future studies and clinical approaches, but are still in early stages of translational impact.

Abstract in brief

  • The study explains how JAK-STAT signaling influences the NFB pathway in chronic lymphocytic leukemia (CLL), affecting the expression of BclXL and determining whether cancer cells are sensitive or resistant to the drug venetoclax.
  • IL21 through STAT3 suppresses BclXL expression by interfering with NFB, while IL4 via STAT6 enhances BclXL levels, with both cytokines affecting BclXL transcription by binding to its promoter, impacting drug response.
  • Inhibiting NFB-inducing kinase NIK disrupts the crosstalk between JAK-STAT and NFB pathways, restoring sensitivity to venetoclax, and revealing new potential targets for overcoming resistance in CLL treatment.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Molecular Oncology
@MolOncology · X

Mar 1, 2023 · 7 likes · 1 share · 2,200 followers View post →
Fábio Fonseca
@FbioFon84085623 · X

RT @MolOncology:

Mar 1, 2023 · 1 share · 587 followers View post →

All mentions

Fábio Fonseca
@FbioFon84085623 · X

RT @MolOncology:

Mar 1, 2023 · 1 share · 587 followers View post →
Molecular Oncology
@MolOncology · X

Mar 1, 2023 · 7 likes · 1 share · 2,200 followers View post →